Publication | Closed Access
Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine
43
Citations
26
References
2010
Year
Good tolerability, feasibility of prolonged treatment, antitumor activity, and favorable pharmacologic profile support further investigation of this combination.
| Year | Citations | |
|---|---|---|
Page 1
Page 1